On the evening of the 24th, Qisda announced plans to launch a public tender offer for 13.95% of its subsidiary Norbel’s shares, at a cash price of NT$175 per share. Qisda currently holds around 26.72% of Norbel's shares and intends to increase its stake to further strengthen its positioning in the medical retail market, aiming to seize the growing opportunities in the aging population sector.
Based on Norbel’s closing price of NT$157 on the previous day, Qisda’s offer represents a premium of approximately 11.5%. Qisda stated that the maximum number of shares to be acquired in this public tender is 5,220 lots, equivalent to 13.95% of the equity, while the minimum acquisition target is 1,872 lots, or around 5%.
Qisda will submit the tender offer application to the Financial Supervisory Commission (FSC) and make a public announcement. The filing date is expected no later than September 24, with the tender offer starting by September 25. The offer will be deemed successful if the total shares tendered meet the minimum acquisition target and the company secures a non-objection ruling from the Fair Trade Commission.
Peter Chen, Chairman of Qisda, highlighted that the healthcare business is one of the key pillars of Qisda’s transition to a high-value-added industry. With BenQ Hospital leading its medical services and the dual growth engines of medical equipment and pharmaceutical distribution, Qisda aims to provide comprehensive healthcare services to the aging population, ensuring that people not only live longer but also live healthier.
Norbel specializes in the sale of professional pharmaceuticals, medical care, health care products, maternity and infant supplies, and medical beauty products, as well as offering related consulting services. Operating under its chain brand Norbel Baby, Norbel has established a network of 94 large-scale professional chain pharmacies and drugstores across Taiwan. The company boasts over 100 highly specialized pharmacists, each with an average of more than five years of experience.
Resource (mandarin): 佳世達擬公開收購子公司諾貝兒近14%股權 強化醫療零售通路布局
